SPORE in Lymphoma
SPORE in Lymphoma
批准号:
8321631
负责人:
STEVEN H BERNSTEIN
金额:
$229.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-01 至 2014-08-31
关键词:
ArizonaB-Cell NonHodgkins LymphomaB-LymphocytesBiological ModelsBiologyCancer CenterCellsClinicalClinical TrialsCorrelative StudyDevelopmentDiffuseIn VitroLeadLymphomaMantle Cell LymphomaNon-Hodgkin&aposs LymphomaOxidation-ReductionPathologicProteasome InhibitorResearch PersonnelResearch Project GrantsResistanceResourcesSouthwest Oncology GroupTherapeuticTherapeutic AgentsTimeTranslational ResearchUniversitiesaurora kinasebasedesignnovelprograms
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This Lymphoma SPORE application from the James P. Wilmot Cancer Center (JPWCC), University of Rochester, and the Arizona Cancer Center (ACC), University of Arizona provides a broad based, translational research program studying several major unresolved issues in the lymphoma biology. Specifically the projects will focus on several novel, targeted therapeutic agents either in development or approved for the treatment of three of the most common non-Hodgkin's lymphomas, namely diffuse large B-cell, follicular and mantle cell lymphoma. We will initially seek to elucidate mechanisms of action and/or resistance both in vitro, and in carefully developed model systems; then pilot clinical trials with an emphasis on correlative studies will be designed and conducted to validate these mechanisms. Investigators at the JPWCC and the ACC, long-time collaborators, lead each of the programs. The clinical and pathologic resources of the Lymphoma Committee of the Southwest Oncology Group are also integrated into this program. Projects include:
Research Project 1: Targeting Aurora Kinase in Aggressive B-cell non-Hodgkin's Lymphoma,
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL.
Project 3: Potentiating Proteasome Inhibitor Activity in NHL.
Project 4: Characterization of Lymphoma-lnitiating Cells.
期刊论文(28)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1158/1078-0432.ccr-11-2413
发表时间:
2012-04-15
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
[Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W]
通讯作者:
Qi W
DOI:
10.1371/journal.pone.0008115
发表时间:
2009-12-02
期刊:
PloS one
影响因子:
3.7
作者:
[Skalska J, Brookes PS, Nadtochiy SM, Hilchey SP, Jordan CT, Guzman ML, Maggirwar SB, Briehl MM, Bernstein SH]
通讯作者:
Bernstein SH
DOI:
10.1309/ajcp2z0tagmuyjeb
发表时间:
2013-02
期刊:
American journal of clinical pathology
影响因子:
3.5
作者:
[Valentino C, Kendrick S, Johnson N, Gascoyne R, Chan WC, Weisenburger D, Braziel R, Cook JR, Tubbs R, Campo E, Rosenwald A, Ott G, Delabie J, Jaffe E, Zhang W, Brunhoeber P, Nitta H, Grogan T, Rimsza L]
通讯作者:
Rimsza L
DOI:
10.2174/157489208786242322
发表时间:
2008-11
期刊:
Recent patents on anti-cancer drug discovery
影响因子:
2.8
作者:
[Tao X, Chon HS, Fu S, Kavanagh JJ, Hu W]
通讯作者:
Hu W
Demonstration of array-based analysis for highly multiplexed PCR assays application to detection of IGH@-BCL2 translocations in FFPE follicular lymphoma specimens.
演示基于阵列的高度多重 PCR 检测分析应用于检测 FFPE 滤泡性淋巴瘤标本中的 IGH@-BCL2 易位。
DOI:
10.1016/j.jmoldx.2010.11.019
发表时间:
2011
期刊:
The Journal of molecular diagnostics : JMD
影响因子:
--
作者:
[Spence,JaniceM, Rothberg,PaulG, Wang,Nancy, Burack,WRichard]
通讯作者:
Burack,WRichard
共 19 条
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
-
批准号:8068292
-
项目类别:
-
资助金额:$30.84万
-
财政年份:2008
-
负责人:STEVEN H BERNSTEIN
-
依托单位:
P- 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
-
批准号:7507431
-
项目类别:
-
资助金额:$17.23万
-
财政年份:2008
-
负责人:STEVEN H BERNSTEIN
-
依托单位:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
-
批准号:7373337
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2008
-
负责人:STEVEN H BERNSTEIN
-
依托单位:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
-
批准号:8260463
-
项目类别:
-
资助金额:$30.84万
-
财政年份:2008
-
负责人:STEVEN H BERNSTEIN
-
依托单位:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
-
批准号:7817051
-
项目类别:
-
资助金额:$31.79万
-
财政年份:2008
-
负责人:STEVEN H BERNSTEIN
-
依托单位:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
-
批准号:7628573
-
项目类别:
-
资助金额:$31.99万
-
财政年份:2008
-
负责人:STEVEN H BERNSTEIN
-
依托单位:
VACCINE FOR PATIENTS WITH NON HODGKINS LYMPHOMA
-
批准号:6166390
-
项目类别:
-
资助金额:$15.82万
-
财政年份:2000
-
负责人:STEVEN H BERNSTEIN
-
依托单位:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
-
批准号:8131040
-
项目类别:
-
资助金额:$21.95万
-
财政年份:--
-
负责人:STEVEN H BERNSTEIN
-
依托单位:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
-
批准号:8381186
-
项目类别:
-
资助金额:$22.05万
-
财政年份:--
-
负责人:STEVEN H BERNSTEIN
-
依托单位:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
-
批准号:8321622
-
项目类别:
-
资助金额:$20.87万
-
财政年份:--
-
负责人:STEVEN H BERNSTEIN
-
依托单位:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
-
批准号:7905985
-
项目类别:
-
资助金额:$25.74万
-
财政年份:--
-
负责人:STEVEN H BERNSTEIN
-
依托单位: